Motilal Oswal: Divi’s Labs - On A Strong Growth Trajectory

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.Divi’s Laboratories Ltd., an Indian pharma company, is among the top three Active Pharmaceutical Ingredient manufacturers in the world.It is also into manufacturing of Nutraceutical ingredients and Custom synthesis of APIs for global Pharma companies.Major capex to be completed in FY21 - To support commercial manufacturing, the company incurred capex of Rs 13 billion for FY20 and is in the last phase of major capital expenditure (Rs 8 billion capital work in progress).The DC-SEZ and DCV-SEZ units, which were partially commercialized in February- March 2020, would help increase the capacity to drive volumes and better backward integration, in turn growing margins.Increased capacity would also help the company capitalize on the current increase in demand and lock-in customers for their long-term requirements.The outlook remains intact in terms of opportunities post the commercialization of manufacturing facilities. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Motilal Oswal: Divi’s Labs - On A Strong Growth Trajectory

Motilal Oswal: Divi’s Labs - On A Strong Growth Trajectory

Choose a plan